Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 463

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 463
---
 Adjustments The Company is providing the unaudited pro forma condensed combined information for illustrative purposes only and such pro forma information does not represent the consolidated results or financial position of the Company had its acquisition of Kadimastem been completed as of the dates indicated. The companies may have performed differently had they been combined during the periods presented. Specifically, the unaudited pro forma condensed combined financial information does not reflect any cost savings, operating synergies, revenue enhancements or restructuring costs that the combined company may achieve or incur as a result of the acquisition. You should not rely on the unaudited pro forma condensed combined financial information as being indicative of the historical results that would have been achieved had the companies been combined during the periods presented. Further, the unaudited pro forma condensed combined financial information does not purport to project the future financial position or operating results of the combined company. The pro forma adjustments in the unaudited pro forma condensed combined balance sheet as of December31, 2024 and statement of operations for the twelve months ended December31, 2024 are as follows: (A)To record net proceeds of $475,000 in connection sale of 161,290 NLS Common Shares at a purchase price of $3.10 per share on January9, 2025 pursuant to the securities purchase agreement with an accredited investor, dated December4, 2024; (B)To record gross proceeds of $178,699 received in January 2025 related to exercise of warrants for a total of 76,847 NLS Common Shares in connection with the securities purchase agreement with certain accredited investors, dated October9, 2024, and pre -fundedwarrants provided to certain institutional investors upon execution of warrant amendment agreements; (C)To record gross proceeds of $1,900,000 in connection with issuance of 1,212,122 preferred shares of NLS, CHF 0.03 nominal value per share (“Preferred Shares”), issued in a private placement offering with three accredited investors entered on March27, 2025, with a conversion price of $1.65 per share; (D)Adjustment to remove $104,963 of interest expenses related to loans converted at closing as noted above as if merger took place January1, 2024; (E)Adjustment to record additional non -recurringNLS transaction costs of approximately $550,000 for legal, audit and other professional service provider expenses and director and officer tail insurance that were not incurred or accrued as part